• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Monday, August 18, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Cancer

Study holds promise for new pediatric brain tumor treatment

Bioengineer by Bioengineer
October 12, 2018
in Cancer
Reading Time: 3 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

SALT LAKE CITY – New research published in Nature Communications from scientists at Huntsman Cancer Institute (HCI) at the University of Utah (U of U), in collaboration with the Stanford University School of Medicine, shows a specific protein regulates both the initiation of cancer spreading and the self-renewal of cancer cells in medulloblastoma, a type of pediatric brain cancer.

Among children's cancers, brain cancer has the highest mortality for children, with medulloblastoma being one of the most common brain tumors in children. Medulloblastoma usually develops at the base of the brain and spreads through the cerebral spinal fluid (CSF) to the spinal cord or other parts of the brain.

"When medulloblastoma spreads, it's much harder to treat and in many cases is incurable," said the study lead, Samuel Cheshier, MD, PhD, cancer researcher at HCI and associate professor of neurosurgery at the U of U. "The need to understand medulloblastoma and how it spreads is incredibly important in order to know how to treat the cancer and find how to stop the disease from spreading, or metastasizing."

To learn more about the metastasis of medulloblastoma, the research team gathered samples from patients that included a brain tumor sample and a spinal metastasis. Researchers then focused on studying different cancer cell markers and found that NOTCH 1, a protein that resides on the surface of the cells, played an important role in the metastasis of the cancer.

"NOTCH 1 is very important in development, as well as stem cell biology. It tells the stem cell to make another stem cell, or self-renew," said Cheshier. "NOTCH 1 has a unique attribute that makes the cancerous cells more likely to spread and form new tumors, as well as self-renew. Understanding this interaction from signals outside the cells is a major step." Cheshier's team used mouse models to research the NOTCH 1 pathway and test a monoclonal antibody treatment that targets the protein to stop the cancer from spreading.

Now, the research team is working on developing a clinical trial for medulloblastoma using the same treatment tested in the lab. This treatment would be administered directly into the CSF spaces of the brain and spinal cord where the tumors reside. Researchers hope this treatment will result in fewer side effects and lead to a more effective treatment option.

###

This work was in collaboration with, Suzana Kahn, PhD, Siddhartha Mitra, PhD, and Irving Weissman, MD, all at Stanford University School of Medicine, with support by the Pew Latin American Fellowship, Price Family Charitable Fund, Center for Children's Brain Tumors, American Brain Tumor Foundation, Matthew Larson Foundation for Pediatric Brain Tumors, Virginia and D.K. Ludwig Fund for Cancer Research, Lucile Packard Foundation for Children's Health, Child Health Research Institute at Stanford-Tashia and John Morgridge Faculty Scholarship in Pediatric Translational Medicine, NIH-NCATS-CTSA UL1 TR001085, German Cancer Aid (Deutsche Krebshilfe)-P-91650709 , Ty Louis Campbell Foundation-St. Baldrick's Foundation Award, Gifts from Kathryn S.R. Lowry, George Landegger, Rider and Victoria McDowell, Charles Comey and Judith Huang, Colin and Jenna Fisher, Canadian NSERC Discovery Grant, Operating Grant 21089 of the Cancer Research Society of Canada, and R01 NS096368-02.

Huntsman Cancer Institute (HCI) at the University of Utah is the official cancer center of Utah. The cancer campus includes a state-of-the-art cancer specialty hospital as well as two buildings dedicated to cancer research. HCI treats patients with all forms of cancer and is recognized among the best cancer hospitals in the country by U.S. News and World Report. As the only National Cancer Institute (NCI)-Designated Comprehensive Cancer Center in the Mountain West, HCI serves the largest geographic region in the country, drawing patients from Utah, Nevada, Idaho, Wyoming, and Montana. More genes for inherited cancers have been discovered at HCI than at any other cancer center in the world, including genes responsible for hereditary breast, ovarian, colon, head, and neck cancers, along with melanoma. HCI manages the Utah Population Database, the largest genetic database in the world, with information on more than 11 million people linked to genealogies, health records, and vital statistics. HCI was founded by Jon M. and Karen Huntsman.

Media Contact

Amie Parker
[email protected]
801-213-5755

http://www.huntsmancancer.org

https://huntsmancancer.org/newsroom/2018/10/new-pediatric-brain-tumor-treatment.php

Share12Tweet7Share2ShareShareShare1

Related Posts

Loneliness Fuels Depression in Cancer Survivors

Loneliness Fuels Depression in Cancer Survivors

August 16, 2025
Nab-Paclitaxel Combo Outperforms Gemcitabine in Biliary Cancer

Nab-Paclitaxel Combo Outperforms Gemcitabine in Biliary Cancer

August 16, 2025

Comparing Treatments for Advanced Esophageal Cancer

August 16, 2025

Immune Checkpoint Inhibitors Show Promise in Unknown Cancers

August 16, 2025
Please login to join discussion

POPULAR NEWS

  • blank

    Molecules in Focus: Capturing the Timeless Dance of Particles

    140 shares
    Share 56 Tweet 35
  • Neuropsychiatric Risks Linked to COVID-19 Revealed

    79 shares
    Share 32 Tweet 20
  • Modified DASH Diet Reduces Blood Sugar Levels in Adults with Type 2 Diabetes, Clinical Trial Finds

    59 shares
    Share 24 Tweet 15
  • Predicting Colorectal Cancer Using Lifestyle Factors

    47 shares
    Share 19 Tweet 12

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

New Metabolic Inflammation Model Explains Teen Reproductive Issues

Mpox Virus Impact in SIVmac239-Infected Macaques

Epigenetic Mechanisms Shaping Thyroid Cancer Therapy

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.